Multicenter Clinical Study on Robotic-Assisted Surgical Management of Posterior Cruciate Ligament Tibial Avulsion Fractures
2026年5月4日 更新者:YujiakuoTHU、Beijing Tsinghua Chang Gung Hospital
The primary objective of this clinical trial is to evaluate the efficacy of robotic-assisted surgery in the management of posterior cruciate ligament (PCL) avulsion fractures involving the tibial insertion site of the cruciate ligament.
Specifically, the study seeks to determine: (1) whether robotic-assisted surgery yields superior anatomical reduction accuracy-particularly in restoring the native position of the tibial avulsion fragment-compared with conventional open reduction and internal fixation (ORIF); and (2) whether such improved precision translates into enhanced long-term functional recovery of the knee joint.
調査の概要
状態
まだ募集していません
詳細な説明
Patients diagnosed with posterior cruciate ligament (PCL) tibial avulsion fractures-confirmed according to established radiographic and clinical diagnostic criteria-were prospectively enrolled from three geographically distinct regional medical centers.
Prior to enrollment, all participants received comprehensive oral and written information detailing the study's objectives, methodology, potential risks and benefits, and the two comparative surgical interventions: robotic-assisted fixation and conventional open reduction and internal fixation (ORIF).
Written informed consent was obtained from each participant following a mandatory reflection period and prior to randomization or any study-related procedures.
All enrolled patients underwent standardized preoperative imaging, including anteroposterior and lateral radiographs of the knee, computed tomography (CT), and magnetic resonance imaging (MRI).
Imaging interpretation was performed independently by two board-certified musculoskeletal radiologists blinded to group allocation; consensus adjudication resolved discrepancies.
Radiological assessment confirmed diagnosis, classified fracture morphology using the Meyers-McKeever classification , and verified adherence to prespecified inclusion and exclusion criteria.
Participants were then allocated in a 1:1 ratio to either the robotic-assisted surgery group (intervention group) or the ORIF group (control group) via centralized, stratified randomization-stratified by ageand fracture type .
Baseline demographic, clinical, and functional assessments-including physical examination and validated patient-reported outcome measures (e.g., IKDC subjective score)-were completed preoperatively.
All surgical procedures were performed by senior orthopedic surgeons with subspecialty expertise in knee trauma, either directly or under their immediate supervision, to ensure procedural fidelity and minimize interoperator variability.
Primary and secondary outcomes were assessed at prespecified time points using objective, validated, and reproducible metrics.
Radiographic evaluation of reduction accuracy entailed measurement of maximal sagittal displacement of the avulsed fragment on postoperative CT scans acquired within 72 ± 24 hours after surgery.
The IKDC subjective score was collected at 24 weeks (±2 weeks) and 12 months (±1 month) postoperatively.
Fracture union was determined radiologically using CT criteria and knee range of motion (ROM) was measured using a standard goniometer at 12 weeks (±1 week) and 24 weeks (±2 weeks).
Intraoperative process metrics-including operative duration, intraoperative fluoroscopic exposure count, estimated blood loss (measured gravimetrically and volumetrically), and incidence of adverse events (e.g., surgical site infection, neurovascular injury, implant-related complications, or unplanned reoperation)-were systematically documented and compared between groups.
Randomization was implemented using a computer-generated, permuted-block randomization sequence managed centrally and stratified as noted above.
Statistical analyses adhered to a prespecified analysis plan: normality of continuous variables was assessed using the Shapiro-Wilk test; normally distributed data are presented as mean ± standard deviation and compared using independent-samples t-tests; non-normally distributed data are reported as median (interquartile range) and analyzed using the Mann-Whitney U test.
Missing data were addressed via multiple imputation , followed by sensitivity analyses using complete-case and worst-case scenarios.
Categorical variables are expressed as frequency (percentage) and compared using the chi-square test or Fisher's exact test, as appropriate.
研究の種類
介入
入学 (推定)
22
段階
- 適用できない
連絡先と場所
このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。
研究連絡先
- 名前:Yu Jia-kuo, MD,Phd
- 電話番号:+86 133 3103 1448
- メール:yujiakuo@tsinghua.edu.cn
研究連絡先のバックアップ
- 名前:Liu Kui, MD
- 電話番号:+86 15932650850
- メール:liukui8153@sina.com
研究場所
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、102218
- Beijing Tsinghua Changgung Hospital
-
コンタクト:
- Liu Kui
- 電話番号:+8615932650850
- メール:liukui8153@sina.com
-
-
参加基準
研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
いいえ
説明
Inclusion Criteria:
Age ≥ 18 years
- Acute closed tibial avulsion fracture, with surgery performed within 3 weeks of injury ③ Radiographically confirmed Meyers-McKeever classification Type II or III fracture ④ Absence of absolute contraindications to surgical intervention ⑤ Provision of voluntary, written informed consent prior to enrollment
Exclusion Criteria:
Pathological fractures or complex ipsilateral injuries, including concomitant fractures at other anatomical sites.
Prior ipsilateral knee joint surgery. ③. Significant vascular or neurological compromise.
Acute meniscal tears, acute anterior cruciate ligament (ACL) ruptures, or acute injuries to the medial or lateral collateral ligaments.
- Compromised local soft tissue integrity, including open fractures. ⑥. Withdrawal from the study or loss to follow-up despite having provided written informed consent.
研究計画
このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Experimental group
Perform surgical robot-assisted arthroscopic surgery
|
Experimental group: Robot-assisted arthroscopic surgery
|
|
他の:Control group
Traditional posterior incision reduction and internal fixation surgery is performed
|
Control group: incisional reduction and internal fixation surgery
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
the quality of surgical reduction
時間枠:72 hours (±24 hours) after the surgery
|
In the CT scan images obtained approximately 72 hours (±24 hours) after the surgery, the maximum distance between the fracture fragments was measured on the sagittal plane.
|
72 hours (±24 hours) after the surgery
|
協力者と研究者
ここでは、この調査に関係する人々や組織を見つけることができます。
捜査官
- 主任研究者:Yu Jia-kuo、Beijing Tsinghua Changgeng Hospital
研究記録日
これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。
主要日程の研究
研究開始 (推定)
2026年5月10日
一次修了 (推定)
2030年12月31日
研究の完了 (推定)
2030年12月31日
試験登録日
最初に提出
2026年4月12日
QC基準を満たした最初の提出物
2026年5月4日
最初の投稿 (実際)
2026年5月8日
学習記録の更新
投稿された最後の更新 (実際)
2026年5月8日
QC基準を満たした最後の更新が送信されました
2026年5月4日
最終確認日
2026年5月1日
詳しくは
本研究に関する用語
その他の研究ID番号
- 26490-4-01
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
はい
IPD プランの説明
The original dataset will be made available to the collaborating research team no later than 12 months following the completion of the clinical trial.
Subsequently, de-identified data will be shared via a secure, encrypted transmission protocol.
Any use of the data is strictly contingent upon prior written approval from the principal investigator and formal authorization by the institutional ethics review board, and shall be limited exclusively to peer-reviewed scientific research activities.
IPD 共有時間枠
The original data will be transferred to the collaborating research team within 12 months following the completion of the clinical trial and will remain accessible to them for a period of two years.
IPD 共有アクセス基準
Within a defined timeframe following the conclusion of the trial, the collaborative research team may access the data repository and share de-identified data-including treatment records, follow-up assessments, and laboratory results-via secure data transmission methods.
Any use of such data requires prior written agreement from the Principal Investigator and formal approval from the relevant Ethics Committee, and is strictly limited to scientific research purposes.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- ICF
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
いいえ
米国FDA規制機器製品の研究
いいえ
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。